Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
Novartis AG halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s disease, the latest in a long history of failed efforts to find a cure for the deadly condition.
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
Novartis AG shareholder Artisan Partners has called for a shakeup of the company's board and an improvement in its dealmaking strategy. This demand follows a significant decline in Novartis shares after three major clinical trial setbacks.
Novartis was first with a trial that fell short.
Novartis and Ionis' drug designed to lower Lp(a) failed to reduce cardiovascular risk in a key trial, leading to a significant selloff in biotech stocks. The failure has raised concerns about the efficacy of emerging heart medications and has cast doubt on similar drugs from competitors like Amgen and Lilly.
European stocks were steady on Tuesday, with heavyweight Novartis AG weighing on the market after suffering its third clinical-trial setback in a week.
Novartis suffered its third clinical-trial setback in a week after del-desiran, a treatment for a rare muscle-wasting disease, failed a late-stage study.
Novartis announced that its oral multiple sclerosis medication, remibrutinib, succeeded in two large studies. The results have led to a surge in Novartis stock, reflecting investor confidence in the drug's potential impact on the market.
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events. Side effects observed in testing have led Novartis to halt development.
Novartis AG reported higher-than-expected profit last quarter as newer cancer medicines offset the aging blockbuster Entresto’s generic hit, signaling a return to growth.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Novartis halts ALS drug development after mid-stage trial failure
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Novartis: More Pain on the Way?
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Novartis's failed trial for cholesterol drug leads to broad biopharma selloff
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market
Pharma major plummets over 10% after third trial disappointment in a week
Novartis announces trial setback on del-desiran drug
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
Novartis shares down as failed cholesterol drug study increases pipeline pressure
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Ionis, Novartis' key experimental heart drug fails in late-stage trial